Advertisement

Discovery of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors

  • Qian Xie
  • Jingjing Wang
  • Miao Liu
  • Xin Wang
  • Di Jiao
  • Qingqing Ma
  • Zhe Jin
  • Qingguo Meng
  • Chun HuEmail author
Original Research
  • 18 Downloads

Abstract

Small molecule tyrosine kinase inhibitors (TKIs) targeting at epidermal growth factor receptor (EGFR) in recent years have made great progress in the treatment of advanced non-small cell cancer (NSCLC). Although as the first-line treatment for sensitizing EGFR mutation-positive metastatic NSCLC, gefitinib has also behaved quite a lot of side effect and EGFR tolerance. Herein, a novel series of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives were designed and synthesized, and screened for their inhibitory activity on the EGFR high-expressing human lung adenocarcinoma cell line A549 and human large cell lung cancer cell line NCI-H460 by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide colorimetric assay. The calculated IC50 values were reported. Compound 8h demonstrated the most potent inhibitory activity (IC50 = 9.57 ± 2.20 μmol L–1 for A549 and IC50 = 13.04 ± 1.21 μmol L–1 for NCI-H460), comparable to the positive-control gefitinib (IC50 = 8.58 ± 1.65 μmol L–1 for A549 and IC50 = 18.66 ± 5.01 μmol L–1 for NCI-H460). Conclusively, 7-bromo- 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the EGFR–TKIs were discovered, and could be used as potential leading compounds for further research.

Keywords

EGFR Inhibitors Heterocycle Synthesis Anticancer activities 

Notes

Acknowledgements

This work was supported by the National Science Foundation of China (NSFC) for the grant No. 21342006 and the Program for Innovative Research Team of the Ministry of Education of China for the grant No. IRT_14R36. We thank Molegro ApS for kindly providing a free evaluation copy of their software package and Schrödinger, LLC for allowing the use of PyMOL Molecular Graphics System.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with animals, performed by any of the authors. Informed consent was obtained from all individual participants included in the study.

Supplementary material

44_2019_2354_MOESM1_ESM.doc (5.5 mb)
Supplementary Information

References

  1. Adly ME, Gedawy EM, El-Malah AA, El-Telbany FA (2018) Synthesis of novel thieno[2,3-d]pyrimidine derivatives and rvaluation of Theircytotoxicity and EGFR inhibitory activity. Anticancer Agents Med Chem 18(5):747–756CrossRefGoogle Scholar
  2. Cagniant P, Cagniant D (1966) Contibution àl’étude des hétérocycles soufrés condensés.Dérivés du dihydro-5,6 4H thiéno-[2,3-b]-thiopyranne, du dihydro-5,6 7H thiéno [3,2-b]-thiopyranne et de la tétrahydro-5,6,7,8 thiéno[3,2-b]-thiépinne. Bull Soc Chim Fr 7:2172–2179Google Scholar
  3. Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP (2010) Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 53(13):4980–4988CrossRefGoogle Scholar
  4. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874CrossRefGoogle Scholar
  5. Guo ZR (2008) Strategy of molecular drug design: pharmacophore and scaffold hopping. Chin J Med Chem 18:147–157Google Scholar
  6. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137–139CrossRefGoogle Scholar
  7. Ke J, Lu Q, Wang X, Sun R, Jin Z, Zhan X, Hu J, Wan DCC, Hu C (2018) Discovery of 4,5-Dihydro-1H-thieno[2′,3′:2,3]thiepino[4,5-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors. Molecules 23:1980CrossRefGoogle Scholar
  8. Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K (2015) Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 4:156–164Google Scholar
  9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 361:947–957CrossRefGoogle Scholar
  10. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immun Methods 65:55–63CrossRefGoogle Scholar
  11. National Comprehensive Cancer Network. Non-small Cell Lung Cancer (Version 2, 2016). Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 2015-12-01
  12. Neumann CS, Fujimori DG, Walsh CT (2008) Halogenation strategies in natural product biosynthesis. Chem Biol 15:99–109CrossRefGoogle Scholar
  13. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73CrossRefGoogle Scholar
  14. Park JH, Liu Y, Lemmon MA, Radhakrishnan R (2012) Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 448:417–423CrossRefGoogle Scholar
  15. Parkin DM, Bray FB, Pisani P (2005) Global cancer statistics. CA Cancer J Clin 55(2):74–108CrossRefGoogle Scholar
  16. Ponticello GS, Freedman MB, Habecker CN, Habecker CN, Holloway MK, Amato JS, Conn RS, Baldwin JJ (1988) Utilization of α, β-unsaturated acids as Michael acceptors for the synthesis of thieno[2,3-b]thiopyrans. J Org Chem 1988 53:9–13Google Scholar
  17. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced nonsmall cell lung cancer. New Engl J Med 346:92–98CrossRefGoogle Scholar
  18. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181CrossRefGoogle Scholar
  19. Sun B, Zhang J, Yin XE, Xu Y, Zhang FR, Huang YS, Wang JH, Wang GQ, Hu C (2016) Synthesis, characterization and biological activity of thieno[2,3-d]pyrimidine derivatives as the epidermal growth factor receptor inhibitors. Lat Am J Pharm 35:570–577Google Scholar
  20. Sun J, Wang XY, Lv PC, Zhu HL (2015) Discovery of a series of novel phenylpiperazine derivatives as egfr tk inhibitors. Sci Rep 5:13934CrossRefGoogle Scholar
  21. Sun R, Song J, Zhao H, Yan CL, Zhang AJ, Koirala D, Li DW, Hu C (2011) Synthesis and anti-tumor activity of 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives. J Chin Pharm Sci 20:26–34Google Scholar
  22. Thomsen R, Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49(11):3315–3321CrossRefGoogle Scholar
  23. Wang JJ, Yin BZ, Jiang GJ, Imafuku K (1990) Synthesis of isochroman-fused pyrazolone and pyrimidine derivatives. J Heterocycl Chem 27:1181–1184CrossRefGoogle Scholar
  24. Wissner A, Mansour TS (2008) The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm 2008 341(8):465–477Google Scholar
  25. Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, Caferro TR, Dickerson SH, Dickson HD, Donaldson KH, Gaul M, Griffin RJ, Hassell AM, Keith B, Mullin R, Petrov KG, Reno MJ, Rusnak DW, Tadepalli SM, Ulrich JC, Wagner CD, Vanderwall DE, Waterson AG, Williams JD, White WL, Uehling DE (2008) 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Proc Natl Acad Sci USA 105(8):2773–2778CrossRefGoogle Scholar
  26. Wu CH, Coumar MS, Chu CY, Lin WH, Chen YR, Chen CT, Shiao HY, Rafi S, Wang SY, Hsu H, Chen CH, Chang CY, Chang TY, Lien TW, Fang MY, Yeh KC, Chen CP, Yeh TK, Hsieh SH, Hsu JT, Liao CC, Chao YS, Hsieh HP (2010) Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. J Med Chem 53(20):7316–7326CrossRefGoogle Scholar
  27. Zhang HQ, Gong FH, Li CG, Zhang C, Wang YJ, Xu YG, Sun LP (2016) Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. Eur J Med Chem 109:371–379CrossRefGoogle Scholar
  28. Zhang L, Deng XS, Zhang C, Meng GP, Wu JF, Li XS, Zhao QC, Hu C (2017) Design, synthesis and cytotoxic evaluation of a novel series of benzo[d]thiazole-2-carboxamide derivatives as potential EGFR inhibitors. Med Chem Res 26(9):2180–2189CrossRefGoogle Scholar
  29. Zhao Y, Wu XR, Yin JG, Wang JJ (2002) Synthesis of isochromano[4,3-C]pyrazole substituted with biheterocycle at 3-position. J Yantai Univ Nat Sci Eng Ed 15:113–117Google Scholar
  30. Zhou W, Ercan D, Jänne PA, Gray NS (2011) Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett 21(2):638–643CrossRefGoogle Scholar
  31. Zhou XF, Guo JL, Ji YM, Pan GF, Liu T, Zhu H, Zhao JP (2016) Reciprocal negative regulation between EGFR and DEPTOR plays an important role in the progression of lung adenocarcinoma. Mol Cancer Res 14:448–457CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Key Laboratory of Structure-based Drug Design & Discovery, Ministry of EducationShenyang Pharmaceutical UniversityShenyangChina
  2. 2.Department of PharmacyYantai UniveristyYantaiChina

Personalised recommendations